Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01582204
Recruitment Status : Active, not recruiting
First Posted : April 20, 2012
Last Update Posted : June 10, 2019
Sponsor:
Collaborator:
Telix Pharmaceutical
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020